Nitric oxide in malignant astrocytes;El monóxido de nitrógeno en los astrocitomas malignos

Revista de Neurologia

Volumn 40, Issue 7, 2005, Pages 437-440

  Esteban, Francisco José ^a   Horcajadas, A ^b   El Rubaidi, O ^c   Luque Barona, R ^c   Ibanez G ^b   Garcia Carriazo A ^c   Segovia, M ^a   Del Moral Leal, M L ^a  

^a UNIVERSITY OF JAÉN   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Hospital Neurotraumatológico   (Spain)

Author keywords

Chemotherapy; Glioblastoma; Nitrosoglutathione; Nitrotyrosine; p53; Radiotherapy

Indexed keywords

CARMUSTINE; GLUTATHIONE; NITRIC OXIDE; PROTEIN P53; TEMOZOLOMIDE;

ASTROCYTE; ASTROCYTOMA; BLOOD VESSEL REACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CELL TYPE; CLINICAL FEATURE; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); REVIEW; TUMOR GROWTH; BRAIN TUMOR; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GENES, P53; HUMANS; NITRIC OXIDE;

EID: 20844435635     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4007.2004396     Document Type: Review

References (28)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361: 323-31.
2. Castro MG, Cowen R, Williamson IK, David A, Jiménez-Dalmaroni MJ, Yuan X, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71-108.
3. Collins VP. Cellular mechanisms targeted during astrocytoma progression. Cancer Lett 2002; 188: 1-7.
4. Dai C, Holland EC. Glioma models. Biochim Biophys Acta 2001; 1551: 19-27.
5. Reilly KM. Jacks T. Genetically engineered mouse models of astrocytoma: GEMs in the rough? Semin Cancer Biol 2001; 11: 177-91.
6. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-58.
7. Peinado MA, Del Moral ML, Martínez-Lara E, Siles E, Hernández R, Pedrosa JA, et al. Role of the nitric oxide system in the aged brain. Recent Research in Developmental Biochemistry 2003; 4: 185-92.
8. Klostergaard J, Leroux ME, Hung MC. Cellular models of macrophage tumoricidal effector mechanisms in vitro. Characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J Immunol 1991; 147: 2802-8.
9. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 1994; 91: 9407-11.
10. Feinstein DL, Galea E, Roberts S, Berquist H, Wang H, Reis DJ. Induction of nitric oxide synthase in rat C6 glioma cells. J Neurochem 1994; 62: 315-21.
11. Fujisawa H, Ogura T, Hokari A, Weisz A, Yamashita J, Esumi H. Inducible nitric oxide synthase in a human glioblastoma cell line. J Neurochem 1995; 64: 85-91.
12. Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H. Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem 1994; 63: 140-5
13. Bakshi A, Nag TC, Wadhwa S, Mahapatra AK, Sarkar C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J Neurol Sci 1998; 155: 196-203.
14. Ellie E, Loiseau H, Lafond F, Arsaut J, Demotes-Mainard J. Differential expression of inducible nitric oxide synthase mRNA in human brain tumours. Neuroreport 1995; 7: 294-6.
15. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 2000; 50: 139-48.
16. Reiter CD, Teng RJ, Beckman JS. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 2000; 275: 32460-6.
17. Siles E, Martínez-Lara E, Cañuelo A, Sánchez M, Hernández R, López-Ramos JC, et al. Age-related changes of the nitric oxide system in the rat brain. Brain Res 2002; 956: 385-92.
18. Uttenthal LO, Alonso D, Fernández AP, Campbell RO, Moro MA, Leza JC, et al. Neuronal and inducible nitric oxide synthase and nitrotyrosine immunoreactivities in the cerebral cortex of the aging rat. Microsc Res Tech 1998; 43: 75-88.
19. Cobbs, CS, Samanta M, Harkins LE, Gillespie GY, Merrick BA, MacMillan-Crow LA. Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences. Arch Biochem Biophys 2001; 394: 167-72.
20. Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Van Meir EG, Samanta M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 2003; 63: 8670-3.
21. Yang DI, Yin JH, Mishra S, Mishra R, Hsu CY. NO-mediated chemoresistance in C6 glioma cells. Ann N Y Acad Sci 2002; 962: 8-17.
22. Yang DI, Yin JH, Ju TC, Chen LS, Hsu CY. Nitric oxide and BCNU chemoresistance in C6 glioma cells: role of S-nitrosoglutathione. Free Radic Biol Med 2004; 36: 1317-28.
23. Yin JH, Yang DI, Chou H, Thompson EM, Xu J, Hsu CY. Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1- nitrosourea in C6 glioma cells. J Pharmacol Exp Ther 2001; 297: 308-15.
24. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-7.
25. Sanderson RJ, Mosbaugh DW. Fidelity and mutational specificity of uracil-initiated base excision DNA repair synthesis in human glioblastoma cell extracts. J Biol Chem 1998; 273: 24822-31.
26. Matsumoto H, Hayashi S, Hatashita M, Shioura H, Ohtsubo T, Kitai R, et al. Induction of radioresistance to accelerated carbon-ion beams in recipient cells by nitric oxide excreted from irradiated donor cells of human glioblastoma. Int J Radiat Biol 2000; 76: 1649-57.
27. Matsumoto H, Hayashi S, Jin Z, Hatashita M, Shioura H, Ohtsubo T, et al. Induction of radioresistance by a nitric oxide-mediated bystander effect. Int Congr Ser 2002; 1236: 295-8.
28. Matsumoto H, Hayashi S, Hatashita M, Ohnishi K, Shioura H, Ohtsubo T, et al. Induction of radioresistance by a nitric oxide-mediated bystander effect. Radiat Res 2001; 155: 387-96.